Please provide your email address to receive an email when new articles are posted on . Perrigo announced that the FDA has approved mometasone furoate monohydrate, an intranasal corticosteroid nasal ...
DUBLIN, March 17, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it has received final approval from the U.S.
No difference in treatment efficacy was observed between intranasal mometasone furoate and saline for the management of sleep-disordered breathing (SDB) symptoms in children, with findings indicating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results